Abstract:Background High-dose-rate brachytherapy (HDR-BT) plays an important role in the treatment of locally recurrent prostate cancer after definitive treatment. The objective of this study is to summarize the efficacy and toxicity of HDR-BT in these patients. Methods We performed a systematic review of PubMed and EMBASE from inception to July 2023. The primary endpoint was relapse-free survival (RFS) in different subgroups, and the secondary endpoint was gastrointestinal (GI) and genitourinary (GU) toxicity. A semi-automated tool (WebPlotDigitizer) and a new Shiny application combined with R software (R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; https://www.R-project.org/) helped to reconstruct survival curves. Results Twenty-six studies met the inclusion criteria for quantitative analysis, including 1447 patients. A total of 761 patients from 13 studies were included in survival reconstruction, and the median RFS time was 61.2 months (57.6–72.0 months). The estimated 2‐, 3‐, and 5‐year rates were 75.9% (95% confidence interval [CI] 72.8 ~ 79.2%), 66.7% (95% CI 63.0 ~ 70.5%), and 52.3% (95% CI 47.5 ~ 57.4%), respectively. Whole-gland irradiation with multiple fractions (≥ 2 F) resulted in better RFS compared with focal gland irradiation with fewer fractions (1 F mostly; hazard ratio [HR]: 0.60, 95% CI 0.47–0.77, p < 0.0001). According to the different median time from primary treatment to salvage therapy (TRS) and median age at recurrence, short median TRS (56–67.2 months vs. 70–120 months; HR 0.52, 95% CI 0.68–0.40; p < 0.0001) and younger median age (60–70 years vs. 71–75 years; HR 0.58, 95% CI 0.46–0.74; p < 0.0001) were positive factors for RFS. The cumulative incidences estimated for grade ≥ 3 acute and late GU toxicities were 1% (95% CI 0 ~ 1%) and 5% (95% CI 4 ~ 7%), respectively. Three patients (3/992) experienced grade ≥ 3 late GI toxicity, and no cases of grade ≥ 3 acute GI toxicity were reported. Conclusion HDR-BT has a high safety profile and good RFS benefit for salvage treatment of radiorecurrent prostate cancer. In terms of RFS, whole-gland irradiation with multiple fractions seems to be better than focal gland irradiation with fewer fractions, while short TRS and younger age are good prognostic factors. In view of the low level of evidence in the included studies and the large heterogeneity of each study, these conclusions still need to be confirmed by randomized controlled trials.

Status of reirradiation with high-dose-rate interstitial brachytherapy in recurrent cervical carcinoma

Image-guided interstitial brachytherapy for recurrent cervical cancer after radiotherapy: A single institution experience

Re-Irradiation for Recurrent Cervical Cancer: A State-of-the-Art Review

Efficacy and safety of 3-dimensional printing noncoplanar template (3D-PNCT)-assisted high-dose-rate interstitial brachytherapy (HDR-ISBT) for reirradiation of recurrent cervical cancer: a prospective cohort

Efficacy of High-Dose-rate Brachytherapy with Different Radiation Source Activities among Cervical Cancer Patients and Risk Factors for Long-Term Outcomes: A 6-Year Retrospective Study.

Research progress on brachytherapy for recurrent cervical cancer

Prognostic factors for IB2-IIIB cervical cancer patients treated by radiation therapy with high-dose-rate brachytherapy in a single-institution study

Image-guided interstitial high-dose-rate brachytherapy for locally recurrent uterine cervical cancer: A single-institution study

Impact of radiation source activity on short- and long-term outcomes of cervical carcinoma patients treated with high-dose-rate brachytherapy: A retrospective cohort study

Dose-Limiting Organs at Risk in Carbon Ion Re-Irradiation of Head and Neck Malignancies: An Individual Risk-Benefit Tradeoff

The study of re-irradiation for head and neck cancer

Application of 192Ir brachytherapy in locally recurrent non-small cell lung cancer

Preliminary Clinical Outcomes and Dosimetry Study on Adaptive Imrt Integrated Hdr Brachytherapy in Local Advanced Uterine Cervical Cancer.

Preliminary Study of Intensity-Modulated Radiation Therapy for Recurrent Cervical Cancer

PO-0965: 125I Seeds Implantation under Ultrasound Guidance for Local Recurrent Tumor of Head and Neck

Dosimetric parameters and safety analysis of 3D-printing non-coplanar template-assisted interstitial brachytherapy for non-centrally recurrent cervical cancer

Reirradiation for recurrent gynecologic cancer using high-dose-rate brachytherapy in Japan: A multicenter survey on practice patterns and outcomes

High-dose-rate brachytherapy in uterine cervix carcinoma: a comparison of dosimetry and clinical outcomes among three fractionation schedules

Evaluation of the safety and efficacy of high-dose rate brachytherapy for radiorecurrent prostate cancer: a systematic review and meta-analysis

Preliminary Results of (125)I Interstitial Brachytherapy for Locally Recurrent Parotid Gland Cancer in Previously Irradiated Patients.

Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer